Category: (canakinumab)

Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer

October 25, 2021 Auto Bot 0

Shots: The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or […]

Strike two for Novartis’ lung cancer antibody canakinumab

October 25, 2021 Auto Bot 0

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) […]

Novartis’ canakinumab falls short in phase 3 lung cancer trial

March 9, 2021 Auto Bot 0

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work […]

Novartis’ Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS

November 9, 2020 Auto Bot 0

Shots: The P-lll CAN-COVID trial involves assessing Ilaris (canakinumab) + SOC vs PBO + SoC in 454 patients aged 18-98yrs. with COVID-19 pneumonia and cytokine […]